Accuracy of Five On-Site Immunoassay Drugs-of-Abuse Testing Devices | Zendy

E. Howard Taylor | Zendy; Ernest H. Oertli | Zendy; Johann Wolfgang | Zendy; E. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Accuracy of Five On-Site Immunoassay Drugs-of-Abuse Testing Devices

Author(s) -

E. Howard Taylor,

Ernest H. Oertli,

Johann Wolfgang,

E. Mueller

Publication year - 1999

Publication title -

journal of analytical toxicology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.161

H-Index - 76

eISSN - 1945-2403

pISSN - 0146-4760

DOI - 10.1093/jat/23.2.119

Subject(s) - immunoassay , drugs of abuse , chromatography , drug , metabolite , urine , mass spectrometry , drug detection , medical screening , designer drug , substance abuse detection , chemistry , pharmacology , medicine , immunology , antibody

Many current "on-site" urine drug-testing products claim performance equivalent to laboratory testing. Five commercially available products (PharmScreen, Roche TestCup, Accusign DOA 2, Status DS, and American Bio Medica-Rapid Drug Screen) were challenged with quality-control specimens of known drug metabolite concentrations, 25% above and 25% below the SAMHSA cutoffs, and with known positive and negative donor specimens previously analyzed by immunoassay and gas chromatography-mass spectrometry. The results indicate discrepancies between claims and performance for all products, particularly with amphetamines. The implications for employer-based drug testing are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research